FDA approved DNMT inhibitors 5-azacytidine (Vidaza) and decitabine (5-aza-2’-deoxycytidine) is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The gene discussed is DNMT1; the disease is myelodysplastic syndrome.